Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial
Burtness, Barbara, Bourhis, Jean P, Vermorken, Jan B, Harrington, Kevin J, Cohen, Ezra EWVolume:
15
Language:
english
Journal:
Trials
DOI:
10.1186/1745-6215-15-469
Date:
December, 2014
File:
PDF, 716 KB
english, 2014